Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures
NCT ID: NCT00530855
Last Updated: 2018-07-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
322 participants
INTERVENTIONAL
2008-02-29
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
NCT00552305
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
NCT00955357
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
NCT00655486
Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
NCT02408549
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
NCT00520741
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lacosamide
Lacosamide tablets for dosing 100 -800 mg/day
Lacosamide
50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lacosamide
50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
048
Alabaster, Alabama, United States
010
Birmingham, Alabama, United States
042
Northport, Alabama, United States
009
Phoenix, Arizona, United States
014
Phoenix, Arizona, United States
151
Phoenix, Arizona, United States
103
Tucson, Arizona, United States
102
Jonesboro, Arkansas, United States
007
Little Rock, Arkansas, United States
086
Little Rock, Arkansas, United States
120
La Habra, California, United States
059
Los Angeles, California, United States
021
Santa Monica, California, United States
107
Torrance, California, United States
060
Aurora, Colorado, United States
025
Fairfield, Connecticut, United States
094
Doral, Florida, United States
108
Gainesville, Florida, United States
123
Miami, Florida, United States
132
Miami, Florida, United States
077
Orlando, Florida, United States
049
Panama City, Florida, United States
129
Port Charlotte, Florida, United States
050
Sarasota, Florida, United States
004
Tallahassee, Florida, United States
079
Atlanta, Georgia, United States
058
Boise, Idaho, United States
131
Hines, Illinois, United States
146
Peoria, Illinois, United States
011
Springfield, Illinois, United States
078
Indianapolis, Indiana, United States
073
Ames, Iowa, United States
124
Manhattan, Kansas, United States
023
Wichita, Kansas, United States
160
Wichita, Kansas, United States
164
Lexington, Kentucky, United States
062
Louisville, Kentucky, United States
029
Scarborough, Maine, United States
020
Baltimore, Maryland, United States
034
Baltimore, Maryland, United States
065
Pikesville, Maryland, United States
137
Waldorf, Maryland, United States
041
Detroit, Michigan, United States
030
Golden Valley, Minnesota, United States
071
Hattiesburg, Mississippi, United States
031
Chesterfield, Missouri, United States
066
St Louis, Missouri, United States
017
Lebanon, New Hampshire, United States
067
Voorhees Township, New Jersey, United States
036
Albany, New York, United States
083
Buffalo, New York, United States
069
Cedarhurst, New York, United States
027
New York, New York, United States
122
New York, New York, United States
003
Asheville, North Carolina, United States
063
Durham, North Carolina, United States
117
Wilmington, North Carolina, United States
015
Cleveland, Ohio, United States
061
Columbus, Ohio, United States
002
Toledo, Ohio, United States
147
Oklahoma City, Oklahoma, United States
100
Greensburg, Pennsylvania, United States
032
Philadelphia, Pennsylvania, United States
024
Beaufort, South Carolina, United States
114
Chattanooga, Tennessee, United States
001
Nashville, Tennessee, United States
138
Austin, Texas, United States
022
Dallas, Texas, United States
046
El Paso, Texas, United States
051
Houston, Texas, United States
053
Houston, Texas, United States
098
San Antonio, Texas, United States
136
Layton, Utah, United States
161
Alexandria, Virginia, United States
016
Charlottesville, Virginia, United States
074
Renton, Washington, United States
080
Madison, Wisconsin, United States
421
Capmerdown, New South Wales, Australia
425
Chatswood, New South Wales, Australia
423
Herston, Queensland, Australia
420
Adelaide, South Australia, Australia
427
Parkville, Victoria, Australia
140
Halifax, Nova Scotia, Canada
116
Hamilton, Ontario, Canada
093
London, Ontario, Canada
091
Greenfield Park, Quebec, Canada
110
Montreal, Quebec, Canada
113
Montreal, Quebec, Canada
127
Calgary, , Canada
223
Aarhus, , Denmark
461
Mainz, , Germany
443
Ferrara, , Italy
445
Reggio Calabria, , Italy
447
Torrette Di Ancona, , Italy
284
Częstochowa, , Poland
286
Gdansk, , Poland
282
Gdynia, , Poland
280
Krakow, , Poland
290
Lublin, , Poland
289
Szczecin, , Poland
281
Warsaw, , Poland
287
Warsaw, , Poland
324
Santa Cruz de Tenerife, , Spain
360
Blackpool, , United Kingdom
367
Cornwall, , United Kingdom
364
London, , United Kingdom
369
London, , United Kingdom
363
Middlesbrough, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-005440-25
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
SP0904
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.